AIM ImmunoTech Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AIM ImmunoTech Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $170.0K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $202.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $141.0K | Apr 1, 2024 |
| FY2018 | Dec 31, 2018 | $367.0K | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $437.0K | Apr 1, 2019 |
| FY2014 | Dec 31, 2014 | $197.0K | Mar 19, 2015 |
| FY2013 | Dec 31, 2013 | $36.0K | Mar 14, 2014 |
| FY2013 | Sep 30, 2013 | $36.0K | Mar 14, 2014 |
| FY2013 | Jun 30, 2013 | $36.0K | Mar 14, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $170.0K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $202.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $141.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $135.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $163.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $140.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $367.0K | Mar 30, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $437.0K | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | $92.0K | Mar 30, 2018 |
| FY2017 | Dec 31, 2015 | $133.0K | Mar 30, 2018 |
| FY2016 | Dec 31, 2014 | $197.0K | Mar 31, 2017 |
| FY2015 | Dec 31, 2013 | $150.0K | Mar 29, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.96M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($17.32M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($28.96M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($19.45M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($19.13M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($14.40M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($9.40M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($9.83M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($8.26M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($7.50M) | Mar 30, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.66M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($19.77M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($31.92M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($19.92M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($18.84M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($15.15M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($12.44M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($11.50M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($11.42M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($13.80M) | Mar 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.92M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $6.20M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $10.94M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.99M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.67M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.72M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.65M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.78M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $4.10M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.11M | Mar 30, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.96M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($14.89M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($21.27M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($16.11M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($13.97M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($10.37M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($9.07M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($10.64M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($7.94M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($7.38M) | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $18.0K | Mar 27, 2026 |
| FY2023 | Dec 31, 2022 | $86.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $41.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $22.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $68.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $51.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $20.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $160.0K | Mar 30, 2018 |
| FY2017 | Dec 31, 2015 | $240.0K | Mar 30, 2018 |
| FY2016 | Dec 31, 2014 | $504.0K | Mar 31, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.78M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $8.61M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $19.38M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $40.49M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $57.70M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $64.58M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $20.75M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $13.85M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $14.21M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $18.87M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.57M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $9.93M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $9.15M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.02M | Apr 1, 2024 |
| FY2014 | Dec 31, 2014 | $4.44M | Mar 19, 2015 |
| FY2014 | Dec 31, 2013 | $2.57M | Mar 19, 2015 |
| FY2013 | Dec 31, 2012 | $13.00M | Mar 14, 2014 |
| FY2012 | Dec 31, 2011 | $5.55M | Mar 18, 2013 |
| FY2011 | Dec 31, 2010 | $5.73M | Mar 14, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.78M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($1.32M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $10.23M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | $38.47M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $56.88M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $61.29M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $13.44M | Mar 31, 2022 |
| FY2020 | Sep 30, 2019 | $13.44M | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | $5.58M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $8.70M | Mar 30, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($440.79M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($426.83M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($409.51M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($380.55M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($361.10M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($341.97M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($327.57M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($318.58M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($308.76M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($300.50M) | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.99M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.70M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $5.44M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $27.05M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $32.09M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $38.50M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.47M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $299.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.41M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $2.41M | Apr 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.48M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.81M | Mar 27, 2026 |
| FY2020 | Dec 31, 2020 | $2.11M | Mar 31, 2021 |
| FY2019 | Dec 31, 2019 | $2.32M | Mar 30, 2020 |
| FY2018 | Dec 31, 2018 | $2.52M | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (30) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (30) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.07M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 655,262 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 49.10M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 48.08M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 47.99M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 42.15M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 10.39M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 1.11M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 32.88M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 24.20M | Mar 30, 2018 |